In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 17.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by October 24, 2022. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request for Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 Medical Knowledge MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

DCIS is a proliferation of abnormal, but noninvasive, cells within the ductolobular system of the breast. DCIS is often considered stage 0 breast cancer and accounts for one in five newly diagnosed breast cancers in the US. Without treatment approximately 14-50% of DCIS will advance to invasive cancer. This large variation in disease progression underscores the need for better understanding of DCIS. Identification of DCIS subpopulations with malignant potential may also be reflective of the various forms of more advanced breast cancers and offers a unique opportunity to understand the complex ecosystem of breast cancer. This conference will utilize an interdisciplinary approach to explore the latest advances in the detection, biological understanding, risk assessment, and treatment of DCIS.

With screening mammography now routine, diagnoses of DCIS increased from 1-2% to 23% of all breast cancers each year in the US. It is estimated that without intervention 14-51% of DCIS cases will progress to invasive breast cancers. The large variability in progression is due in part from a dearth of studies about the natural history of DCIS and highlights the need for more information about the heterogeneous pathological and biological traits of DCIS. Despite, or possible because of, the large variability in progression rates all DCIS lesions are treated, and treatment comprises either mastectomy or breast-conserving surgery supplemented with radiotherapy. With the aim of reducing overtreatment, the management of DCIS is evolving towards deescalated and more personalized options. However, there is still much controversy regarding the risk of recurrence or progression with these newer, less aggressive practices.

This conference will be useful to basic, translational and clinical scientists, as well as physicians/practicing oncologists engaged in the research and treatment of breast cancer, particularly for those who treat or manage ductal carcinoma in situ (DCIS). Sessions dedicated to discussing current treatment controversies, surgical management, ongoing clinical trials and advances in pathology and artificial intelligence for the detection of DCIS will be highly relevant to physicians. 

After participating in this CME activity, physicians should be able to:

  1. Compare various uses of artificial intelligence in the detection and diagnosis of DCIS.
  2. Articulate the benefit and limitations of current treatment strategies, including surgery, for DCIS.
  3. Evaluate strategies to quantify tumor heterogeneity and tumor subtype.
  4. Identify the complexities of current model systems and how they could be applied in their own research.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

Planner and Speaker Financial Disclosure Index

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants which will be disclosed at the activity.

Questions about CME?

Please read our frequently asked questions. If you still have questions, contact the Office of CME at (215) 440-9300 or [email protected].